Next Article in Journal / Special Issue
A Proposed Clinical Decision Support Architecture Capable of Supporting Whole Genome Sequence Information
Previous Article in Journal / Special Issue
Genetically Guided Statin Therapy on Statin Perceptions, Adherence, and Cholesterol Lowering: A Pilot Implementation Study in Primary Care Patients
Article Menu

Export Article

Open AccessArticle
J. Pers. Med. 2014, 4(2), 163-175;

Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement

Tufts Center for the Study of Drug Development (Tufts CSDD), Tufts University Medical School, 75 Kneeland Street, Suite 1100, Boston, MA 02111, USA
Author to whom correspondence should be addressed.
Received: 25 November 2013 / Revised: 8 March 2014 / Accepted: 26 March 2014 / Published: 4 April 2014
(This article belongs to the Special Issue Bringing Personalized Medicine into Clinical Practice 2013)
Full-Text   |   PDF [735 KB, uploaded 4 April 2014]   |  


Background: Personalized medicine is gradually emerging as a transformative field. Thus far, seven co-developed drug-diagnostic combinations have been approved and several dozen post-hoc drug-diagnostic combinations (diagnostic approved after the drug). However, barriers remain, particularly with respect to reimbursement. Purpose, methods: This study analyzes barriers facing uptake of drug-diagnostic combinations. We examine Medicare reimbursement in the U.S. of 10 drug-diagnostic combinations on the basis of a formulary review and a survey. Findings: We found that payers reimburse all 10 drugs, but with variable and relatively high patient co-insurance, as well as imposition of formulary restrictions. Payer reimbursement of companion diagnostics is limited and highly variable. In addition, we found that the body of evidence on the clinical- and cost-effectiveness of therapeutics is thin and even less robust for diagnostics. Conclusions, discussion: The high cost of personalized therapeutics and dearth of evidence concerning the comparative clinical effectiveness of drug-diagnostic combinations appear to contribute to high patient cost sharing, imposition of formulary restrictions, and limited and variable reimbursement of companion diagnostics. Our findings point to the need to increase the evidence base supportive of establishing linkage between diagnostic testing and positive health outcomes. View Full-Text
Keywords: Personalized medicine; companion diagnostics; reimbursement; cost-effectiveness; coverage with evidence development Personalized medicine; companion diagnostics; reimbursement; cost-effectiveness; coverage with evidence development

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Cohen, J.P.; Felix, A.E. Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement. J. Pers. Med. 2014, 4, 163-175.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top